Infrequent expression of the cancer-testis antigen, PASD1, in ovarian cancer
MetadataShow full item record
AbstractOvarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Therefore, it is imperative that early-stage biomarkers are identified to enhance the early detection of ovarian cancer. Cancer-testis antigens (CTAs), such as Per ARNT SIM (PAS) domain containing 1 (PASD1), are unique in that their expression is restricted to immunologically restricted sites, such as the testis and placenta, which do not express MHC class I, and cancer, making them ideally positioned to act as targets for immunotherapy as well as potential biomarkers for cancer detection where expressed. We examined the expression of PASD1a and b in a number of cell lines, as well as eight healthy ovary samples, eight normal adjacent ovarian tissues, and 191 ovarian cancer tissues, which were predominantly stage I (n = 164) and stage II (n = 14) disease. We found that despite the positive staining of skin cancer, only one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels. This may reflect the predominantly stage I ovarian cancer samples examined. To examine the restriction of PASD1 expression, we examined endometrial tissue arrays and found no expression in 30 malignant tumor tissues, 23 cases of hyperplasia, or 16 normal endometrial tissues. Our study suggests that the search for a single cancer-testes antigen/biomarker that can detect early ovarian cancer must continue.
CitationKhan, G., Brooks, S.E., Mills, K.I. & Guinn, B.A. (2015) 'Infrequent expression of the cancer-testis antigen, PASD1, in ovarian cancer' Biomarkers in Cancer, Vol 7, pp.31-38.
JournalBiomarkers in Cancer
PubMed Central IDPMC4539101
SponsorsThis work was funded by Research Investment Program funding at the University of Bedfordshire. Thanks to Professor Alison Banham and Mrs Linden Lyne for providing the PASD1 antibody.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/
Showing items related by title, author, creator and subject.
IManageCancer: developing a platform for empowering patients and strengthening self-management in cancer diseasesGraf, Norbert; Hoffman, Stefan; Koumakis, Lefteris; Pravettoni, Gabrielli; Marias, Kostas; Tsiknakis, Manolis; Kiefer, Stefan; Kondylakis, Haridimos; Bucur, Anca; Dong, Feng; et al. (Institute of Electrical and Electronics Engineers Inc., 2017-11-13)Cancer research has led to more cancer patients being cured, and many more enabled to live with their cancer. As such, some cancers are now considered a chronic disease, where patients and their families face the challenge to take an active role in their own care and in some cases in their treatment. To this direction the iManageCancer project aims to provide a cancer specific self-management platform designed according to the needs of patient groups while focusing, in parallel, on the wellbeing of the cancer patient. In this paper, we present the use-case requirements collected using a survey, a workshop and the analysis of three white papers and then we explain the corresponding system architecture. We describe in detail the main technological components of the designed platform, show the current status of development and we discuss further directions of research.